<style>
.w-richtext p,.w-richtext li,.w-richtext td{font-size:18px;line-height:1.65}
.w-richtext h2{font-size:26px;line-height:1.35}
.w-richtext h3{font-size:22px;line-height:1.35}
.w-richtext ul{list-style-type:disc;padding-left:24px;margin:12px 0}
.w-richtext ul li{margin-bottom:8px;line-height:1.65}
.w-richtext .ac-action-plan{background:linear-gradient(135deg,#fffcf4 0%,#fff8ed 100%);border-left:5px solid #9a6841;border-radius:12px;padding:28px 24px;margin:32px 0;box-shadow:0 2px 12px rgba(0,0,0,0.06)}
.article-header-section .article-container{max-width:1080px !important;margin:0 auto !important;padding:0 20px !important}
.article-header-section .article-hero-image{display:block;width:100%;max-width:660px;margin:0}
.article-header-section .article-title{display:block !important;font-family:Georgia,serif;font-size:32px;line-height:1.25;font-weight:700;color:#313743;margin:20px 0 12px 0;text-align:left;max-width:660px}
@media (max-width:767px){.article-header-section .article-title{font-size:26px}.article-header-section .article-hero-image{max-width:100%}}
.ac-article-cta{margin-top:40px;text-align:center}
.ac-article-cta .ac-cta-lead{font-family:Georgia,serif;font-size:17px;color:#555;margin:0 0 16px 0;line-height:1.5}
.ac-article-cta a.ac-nav-cta{display:inline-flex;align-items:center;gap:10px;padding:10px 14px 10px 20px;background:#313743;color:#fff;border:1.5px solid #14D4CD;border-radius:82px;font-family:Inter,sans-serif;font-size:14px;font-weight:600;letter-spacing:0.3px;text-decoration:none;transition:transform 0.15s ease,box-shadow 0.15s ease}
.ac-article-cta a.ac-nav-cta:hover{transform:translateY(-1px);box-shadow:0 6px 18px rgba(20,212,205,0.25)}
.ac-article-cta .ac-nav-cta-arrow{width:28px;height:28px;background:#14D4CD;border-radius:50%;display:inline-flex;align-items:center;justify-content:center;flex-shrink:0}
.ac-article-cta .ac-nav-cta-arrow svg{width:14px;height:14px}
</style>
<p class="publish-date" style="font-size:13px; color:#999; margin-bottom:16px;">Published: May 15, 2026 · Last updated: May 15, 2026</p>
<div class="ac-glance" style="background-color: #ffffff; padding: 20px; border: 2px solid #b0bec5; border-radius: 8px; margin: 20px 0;"><strong>This week's brief at a glance:</strong><ul style="margin: 12px 0; padding-left: 24px;"><li style="margin-bottom:6px;">Lecanemab slowed cognitive decline by 27% over 18 months in early-stage Alzheimer's patients in the pivotal Clarity AD trial (NIA, 2023)</li><li style="margin-bottom:6px;">The FDA granted full traditional approval in July 2023 after originally clearing the drug under accelerated approval six months earlier (National Institute on Aging, 2023)</li><li style="margin-bottom:6px;">Up to 21% of patients in trials developed amyloid-related imaging abnormalities (brain swelling or microbleeds), which is the side effect most consumer coverage understates (Mayo Clinic, 2024)</li></ul></div>
<p>You probably heard the headlines in 2023. The first drug to actually slow Alzheimer's. A breakthrough after 20 years of failed trials. Hope, finally, for the families who have spent decades watching a loved one disappear in slow motion. The drug is called lecanemab, sold under the brand name Leqembi, and the headlines were not wrong. But they were not the whole story either.</p>
<p>What got lost in the celebration is what the drug actually does, who it actually helps, and what the trade-offs look like in real life. The honest answer is more useful than the headline. If you have a parent, a spouse, or a friend asking whether lecanemab is worth considering, here is what the published Tier 1 evidence shows.</p>
<h3>What Lecanemab Actually Does</h3>
<p>Lecanemab is an intravenous monoclonal antibody. It binds to beta-amyloid, a sticky protein that builds up between brain cells decades before symptoms appear and is one of the defining features of Alzheimer's disease. Once bound, the immune system clears the amyloid out.</p>
<p>In the 18-month Clarity AD trial of 1,795 participants, lecanemab slowed the rate of cognitive and functional decline by 27% compared to placebo on the primary endpoint, the Clinical Dementia Rating Sum of Boxes score (<a href="https://www.nia.nih.gov/health/alzheimers-treatment/how-alzheimers-disease-treated" target="_blank" rel="noopener">NIA, 2024</a>). On secondary measures of daily function, the slowdown ranged from 24% to 37%.</p>
<p>A 27% slowdown is not a cure. It is not a reversal. It is a meaningful delay in the rate at which a person loses themselves. For a family in the early stage of this disease, that delay can be the difference between attending a granddaughter's wedding with recognition and not.</p>
<h3>Who Qualifies (And Who Does Not)</h3>
<p>Lecanemab was studied and approved only for adults with mild cognitive impairment or mild dementia stage of Alzheimer's, confirmed by a PET scan or cerebrospinal fluid test showing amyloid pathology. People with moderate or advanced Alzheimer's were not in the trial and do not qualify for treatment.</p>
<p>The eligibility window is narrower than most people realize. By the time many families seek a diagnosis, the disease has progressed past the mild stage. That is why earlier evaluation matters so much when lecanemab is on the table.</p>
<p>The FDA granted lecanemab traditional approval in July 2023, converting it from the accelerated approval pathway that had cleared it six months earlier (<a href="https://www.nia.nih.gov/news/fda-converts-novel-alzheimers-disease-treatment-traditional-approval" target="_blank" rel="noopener">NIA, 2023</a>). Medicare now covers it for patients who meet the early-stage criteria.</p>
<h3>The Side Effect Most People Do Not Hear About</h3>
<p>The most important risk is called amyloid-related imaging abnormalities, or ARIA. As the drug clears amyloid plaques, the surrounding blood vessels can temporarily leak, causing brain swelling (ARIA-E) or small bleeds (ARIA-H). In the Clarity AD trial, 21% of treated patients showed some form of ARIA on MRI, compared to about 9% in the placebo arm.</p>
<p>Most ARIA cases are mild and resolve without symptoms. But about 3% of patients experienced symptomatic ARIA, and rare deaths have been reported, particularly in patients taking blood thinners or carrying two copies of the APOE4 gene variant (<a href="https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/diagnosis-treatment/drc-20350453" target="_blank" rel="noopener">Mayo Clinic, 2024</a>). MRI monitoring during the first months of treatment is now standard.</p>
<p>This is the part that gets minimized in the marketing. The drug works, and the risks are real, and a thoughtful conversation with a specialist is the only way to weigh them for a specific person.</p>
<h3>What This Means for Alzheimer's Research</h3>
<p>Lecanemab is proof of a principle that took two decades and dozens of failed trials to establish: removing amyloid from the brain slows the disease. A second drug, donanemab, has since shown similar effects with a different dosing schedule. More antibody therapies are in late-stage trials.</p>
<p>The research moves forward because organizations like the Alzheimer's Association, the National Institute on Aging, and academic centers continue to fund the trials, the registries, and the basic science that made lecanemab possible. The path from this drug to the next better drug runs through that research.</p>
<p>That is also why Ageless Coach donates a portion of every Pro subscription to the Alzheimer's Foundation for research. Slowing the disease by 27% is the floor, not the ceiling. The next generation of these drugs needs the work to keep going.</p>
<div class="ac-action-plan" style="background: linear-gradient(135deg, #fffcf4 0%, #fff8ed 100%); border-left: 5px solid #9A6841; border-radius: 12px; padding: 28px 24px; margin: 32px 0; box-shadow: 0 2px 12px rgba(0,0,0,0.06);"><div style="display: flex; align-items: center; gap: 10px; margin-bottom: 20px;"><svg width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="#9A6841" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2"/><rect x="9" y="3" width="6" height="4" rx="1"/><path d="M9 14l2 2 4-4"/></svg><span style="font-family: Georgia, serif; font-size: 22px; font-weight: 700; color: #313743;">Your Coach's Recommendations</span></div><div style="display: flex; gap: 14px; margin-bottom: 16px; align-items: flex-start;"><div style="min-width: 36px; width: 36px; height: 36px; background: #9A6841; border-radius: 50%; display: flex; align-items: center; justify-content: center; color: #fff; font-weight: 700; font-size: 16px; flex-shrink: 0;">1</div><div><div style="font-weight: 700; color: #313743; font-size: 15px; margin-bottom: 2px;">If Memory Concerns Have Surfaced, Ask for a Cognitive Evaluation.</div><div style="color: #6b7280; font-size: 13.5px; line-height: 1.5;">The eligibility window for lecanemab is narrow. A primary care doctor can administer the Montreal Cognitive Assessment in 10 minutes and refer to a neurologist if anything looks off.</div></div></div><div style="display: flex; gap: 14px; margin-bottom: 16px; align-items: flex-start;"><div style="min-width: 36px; width: 36px; height: 36px; background: #9A6841; border-radius: 50%; display: flex; align-items: center; justify-content: center; color: #fff; font-weight: 700; font-size: 16px; flex-shrink: 0;">2</div><div><div style="font-weight: 700; color: #313743; font-size: 15px; margin-bottom: 2px;">Ask About APOE4 Status Before Starting Treatment.</div><div style="color: #6b7280; font-size: 13.5px; line-height: 1.5;">People who carry two copies of the APOE4 gene variant face higher ARIA risk on lecanemab. A simple blood or saliva test settles it before infusions begin.</div></div></div><div style="display: flex; gap: 14px; margin-bottom: 20px; align-items: flex-start;"><div style="min-width: 36px; width: 36px; height: 36px; background: #9A6841; border-radius: 50%; display: flex; align-items: center; justify-content: center; color: #fff; font-weight: 700; font-size: 16px; flex-shrink: 0;">3</div><div><div style="font-weight: 700; color: #313743; font-size: 15px; margin-bottom: 2px;">Build the Non-Drug Foundation Regardless of Treatment.</div><div style="color: #6b7280; font-size: 13.5px; line-height: 1.5;">Exercise, sleep, the MIND diet, and social engagement compound with any medication. Lecanemab does not replace these. The drug works better when the foundation is built.</div></div></div><div style="border-top: 1px solid #e5ddd4; margin: 16px 0;"></div><div style="display: flex; justify-content: center; align-items: center; gap: 10px; flex-wrap: wrap;"><button onclick="acPrintPlan()" style="background: none; border: 1px solid #d3cabe; border-radius: 8px; padding: 10px 16px; font-size: 13px; color: #6b7280; cursor: pointer; display: flex; align-items: center; gap: 6px;"><svg width="14" height="14" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><polyline points="6 9 6 2 18 2 18 9"/><path d="M6 18H4a2 2 0 01-2-2v-5a2 2 0 012-2h16a2 2 0 012 2v5a2 2 0 01-2 2h-2"/><rect x="6" y="14" width="12" height="8"/></svg>Print</button></div></div>
<div style="margin-top: 32px; padding-top: 0;">
<div style="width: 60px; height: 2px; background: linear-gradient(90deg, #9A6841, #be7b4c); border-radius: 2px; margin-bottom: 20px;"></div>
<p style="font-family: Georgia, serif; font-size: 16px; font-style: italic; color: #777; margin: 0 0 6px 0; letter-spacing: 0.3px; padding-left: 38px;">To your health,</p>
<div style="display: flex; align-items: center; gap: 4px; margin-bottom: 4px;">
<img src="https://cdn.prod.website-files.com/69be130d412f9c2c202307ef/69c539b9526b266e2cba5521_ageless-coach-logo-black.png" alt="AC" style="width: 34px; height: 34px; object-fit: contain;">
<p style="font-family: Georgia, serif; font-size: 22px; font-weight: 700; color: #313743; margin: 0; letter-spacing: 0.5px;">Ageless Coach</p>
</div>
<p style="font-family: -apple-system, BlinkMacSystemFont, Segoe UI, sans-serif; font-size: 11px; font-weight: 600; color: #be7b4c; letter-spacing: 2px; text-transform: uppercase; margin: 0 0 0 28px;">Age Strong. Live Long.</p>
</div>
<div style="margin-top: 28px; padding-top: 20px; border-top: 1px solid #e5e7eb; text-align: center;">
<p style="font-family: -apple-system, BlinkMacSystemFont, Segoe UI, sans-serif; font-size: 13px; font-weight: 700; color: #6b7280; letter-spacing: 2px; text-transform: uppercase; margin: 0 0 16px 0;">Trusted Sources Behind This Article</p>
<div style="display: flex; justify-content: center; gap: 10px; flex-wrap: wrap;">
<a href="https://www.nia.nih.gov/health/alzheimers-treatment/how-alzheimers-disease-treated" target="_blank" rel="noopener" style="display: inline-block; background: #fff; border: 1.5px solid #9A6841; color: #9A6841; padding: 8px 20px; border-radius: 20px; font-size: 14px; font-weight: 600; letter-spacing: 0.3px; text-decoration: none; transition: background 0.2s ease, color 0.2s ease;">National Institute on Aging</a>
<a href="https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/diagnosis-treatment/drc-20350453" target="_blank" rel="noopener" style="display: inline-block; background: #fff; border: 1.5px solid #9A6841; color: #9A6841; padding: 8px 20px; border-radius: 20px; font-size: 14px; font-weight: 600; letter-spacing: 0.3px; text-decoration: none; transition: background 0.2s ease, color 0.2s ease;">Mayo Clinic</a>
<a href="https://www.nia.nih.gov/news/fda-converts-novel-alzheimers-disease-treatment-traditional-approval" target="_blank" rel="noopener" style="display: inline-block; background: #fff; border: 1.5px solid #9A6841; color: #9A6841; padding: 8px 20px; border-radius: 20px; font-size: 14px; font-weight: 600; letter-spacing: 0.3px; text-decoration: none; transition: background 0.2s ease, color 0.2s ease;">NIA Research News</a>
</div>
</div>
<p style="font-size: 12px; color: #999; margin-top: 40px; line-height: 1.5;"><em>This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reading this article does not create a provider-patient relationship. Always consult your physician or qualified healthcare provider before making changes to your diet, exercise, or health routine. Ageless Coach is not liable for any actions taken based on this information.</em></p>
<div class="ac-faq" style="margin-top:40px; border-top:1px solid #e5e7eb; padding-top:32px;">
<h2 style="font-family:Georgia,serif; font-size:20px; font-weight:700; color:#313743; margin:0 0 20px 0;">Frequently Asked Questions</h2>
<details style="border:1px solid #e5e7eb; border-radius:8px; margin-bottom:10px; overflow:hidden;">
<summary style="padding:14px 18px; font-weight:600; font-size:15px; color:#313743; cursor:pointer; list-style:none; display:flex; justify-content:space-between; align-items:center;">
How do I know if I qualify for lecanemab?
<svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="#9A6841" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><polyline points="6 9 12 15 18 9"/></svg>
</summary>
<div style="padding:0 18px 16px; font-size:18px; color:#555; line-height:1.65;">You need a diagnosis of mild cognitive impairment or mild dementia from Alzheimer's, confirmed by a PET scan or cerebrospinal fluid test showing amyloid buildup. A neurologist or geriatric psychiatrist makes the call. Moderate or advanced Alzheimer's is outside the approved use.</div>
</details>
<details style="border:1px solid #e5e7eb; border-radius:8px; margin-bottom:10px; overflow:hidden;">
<summary style="padding:14px 18px; font-weight:600; font-size:15px; color:#313743; cursor:pointer; list-style:none; display:flex; justify-content:space-between; align-items:center;">
Is lecanemab safe if I take blood thinners?
<svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="#9A6841" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><polyline points="6 9 12 15 18 9"/></svg>
</summary>
<div style="padding:0 18px 16px; font-size:18px; color:#555; line-height:1.65;">Blood thinners raise the risk of the brain bleeding side effect (ARIA-H). Some patients on anticoagulants have been excluded from treatment or required closer MRI monitoring. This is a conversation to have specifically with the prescribing neurologist before starting.</div>
</details>
<details style="border:1px solid #e5e7eb; border-radius:8px; margin-bottom:10px; overflow:hidden;">
<summary style="padding:14px 18px; font-weight:600; font-size:15px; color:#313743; cursor:pointer; list-style:none; display:flex; justify-content:space-between; align-items:center;">
How much does lecanemab cost out of pocket?
<svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="#9A6841" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><polyline points="6 9 12 15 18 9"/></svg>
</summary>
<div style="padding:0 18px 16px; font-size:18px; color:#555; line-height:1.65;">List price runs around $26,500 per year. Medicare Part B covers most of the cost for eligible patients after the 20% coinsurance, which can mean roughly $5,000 per year out of pocket without supplemental coverage. Medigap or Medicare Advantage plans often cover the coinsurance.</div>
</details>
<details style="border:1px solid #e5e7eb; border-radius:8px; margin-bottom:10px; overflow:hidden;">
<summary style="padding:14px 18px; font-weight:600; font-size:15px; color:#313743; cursor:pointer; list-style:none; display:flex; justify-content:space-between; align-items:center;">
How is lecanemab actually given?
<svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="#9A6841" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><polyline points="6 9 12 15 18 9"/></svg>
</summary>
<div style="padding:0 18px 16px; font-size:18px; color:#555; line-height:1.65;">It is an intravenous infusion given every two weeks at a clinic or infusion center. Each session takes about an hour. Patients typically receive MRI scans before treatment starts and at intervals during the first six months to monitor for ARIA.</div>
</details>
<details style="border:1px solid #e5e7eb; border-radius:8px; margin-bottom:10px; overflow:hidden;">
<summary style="padding:14px 18px; font-weight:600; font-size:15px; color:#313743; cursor:pointer; list-style:none; display:flex; justify-content:space-between; align-items:center;">
What is the difference between lecanemab and donanemab?
<svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="#9A6841" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><polyline points="6 9 12 15 18 9"/></svg>
</summary>
<div style="padding:0 18px 16px; font-size:18px; color:#555; line-height:1.65;">Both are anti-amyloid antibodies given by infusion. Donanemab is dosed every four weeks rather than two, and trials suggest patients can stop the drug once amyloid is cleared, which lecanemab does not allow. ARIA risk profiles are similar. Specialists pick between them based on individual factors.</div>
</details>
<details style="border:1px solid #e5e7eb; border-radius:8px; margin-bottom:10px; overflow:hidden;">
<summary style="padding:14px 18px; font-weight:600; font-size:15px; color:#313743; cursor:pointer; list-style:none; display:flex; justify-content:space-between; align-items:center;">
Can I take lecanemab if I have memory issues but no Alzheimer's diagnosis?
<svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="#9A6841" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><polyline points="6 9 12 15 18 9"/></svg>
</summary>
<div style="padding:0 18px 16px; font-size:18px; color:#555; line-height:1.65;">No. Approval requires confirmed Alzheimer's pathology on PET scan or spinal fluid test. Memory complaints alone, normal age-related forgetfulness, or other dementia types like vascular dementia or Lewy body dementia are outside the approved use.</div>
</details>
<details style="border:1px solid #e5e7eb; border-radius:8px; margin-bottom:10px; overflow:hidden;">
<summary style="padding:14px 18px; font-weight:600; font-size:15px; color:#313743; cursor:pointer; list-style:none; display:flex; justify-content:space-between; align-items:center;">
What happens if I stop taking lecanemab?
<svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="#9A6841" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" aria-hidden="true"><polyline points="6 9 12 15 18 9"/></svg>
</summary>
<div style="padding:0 18px 16px; font-size:18px; color:#555; line-height:1.65;">Open-label extension data suggest the cognitive benefit narrows over time once treatment stops, because amyloid begins to re-accumulate. Most current protocols recommend continuing treatment as long as the patient is tolerating it and remains in early-stage disease.</div>
</details>
</div>
<div class="ac-article-cta">
<p class="ac-cta-lead">Want one verified-science article like this every week?</p>
<a href="/newsletter" class="ac-nav-cta">
Get Better Health, Weekly
<span class="ac-nav-cta-arrow">
<svg viewBox="0 0 18 18" fill="none" xmlns="http://www.w3.org/2000/svg" aria-hidden="true"><path d="M4.24 13.59L12.73 5.11" stroke="#0D1B2A" stroke-width="1.8"/><path d="M4.95 4.4H13.44V12.89" stroke="#0D1B2A" stroke-width="1.8"/></svg>
</span>
</a>
</div>
Get Better Health, Weekly